A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB
Phase of Trial: Phase I/II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Delamanid (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- 05 Feb 2018 Status changed from not yet recruiting to recruiting.
- 14 Dec 2017 Planned initiation date changed from 1 Nov 2017 to 1 Jan 2018.
- 04 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Nov 2017.